Holen Sie sich die Stockscreener-App
1.68
3.57%
-0.07
Schlusskurs vom Vortag:
$1.75
Offen:
$1.75
24-Stunden-Volumen:
311.88K
Relative Volume:
0.07
Marktkapitalisierung:
$143.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-59.69M
KGV:
-1.2086
EPS:
-1.39
Netto-Cashflow:
$-46.54M
1W Leistung:
+6.81%
1M Leistung:
-0.73%
6M Leistung:
-13.90%
1J Leistung:
-16.87%
1-Tages-Spanne:
$1.68
$1.76
1-Wochen-Bereich:
$1.53
$1.79
52-Wochen-Spanne:
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Firmenname
Milestone Pharmaceuticals Inc
Sektor
Branche
Telefon
(514) 336-0444
Adresse
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.68 | 149.05M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.80 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.16 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.52 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.65 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.37 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-09-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-06-20 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-03 | Eingeleitet | Cowen | Outperform |
| 2019-06-03 | Eingeleitet | Jefferies | Buy |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
Milestone Pharmaceuticals Sets March 20 Call for 2025 Results and Business Update - TipRanks
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 - Bitget
Milestone Pharma sets Mar. 20 call to review 2025 results - Stock Titan
Swing Trade: What is the long term forecast for Milestone Pharmaceuticals Inc stockWeekly Profit Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Milestone Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Stock Report: Does Milestone Pharmaceuticals Inc have consistent dividend growthRecession Risk & Safe Entry Point Alerts - baoquankhu1.vn
Earnings Report: Should I invest in Milestone Pharmaceuticals Inc before earningsShare Buyback & Growth Oriented Trading Recommendations - baoquankhu1.vn
Milestone Pharmaceuticals Inc. $MIST Shares Purchased by Propel Bio Management LLC - MarketBeat
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Thursday - MarketBeat
MIST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Trend Review: Can Milestone Pharmaceuticals Inc beat the S P 500Earnings Growth Report & Expert Curated Trade Setups - baoquankhu1.vn
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update - MarketBeat
Aug Outlook: Can Milestone Pharmaceuticals Inc beat the S P 500Portfolio Gains Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Milestone Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - Bitget
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Zacks Research Downgrades Milestone Pharmaceuticals (NASDAQ:MIST) to Hold - MarketBeat
BlackRock HPS Credit Strategies Fund's Milestone Pharmaceuticals Inc(MIST) Holding History - GuruFocus
Risk Recap: What is the long term forecast for Milestone Pharmaceuticals Inc stockJuly 2025 Sector Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Does Milestone Pharmaceuticals Inc. have consistent dividend growthQuarterly Investment Review & AI Powered Buy and Sell Recommendations - mfd.ru
What is Milestone Pharmaceuticals Inc.’s book value per shareJuly 2025 Retail & Capital Efficient Trade Techniques - mfd.ru
Is Milestone Pharmaceuticals Inc.’s ROIC above industry average2025 Top Gainers & Safe Entry Trade Signal Reports - mfd.ru
Milestone Pharmaceuticals - WCIV
Why Milestone Pharmaceuticals Inc. stock is a value investor pick2025 Bull vs Bear & Community Consensus Trade Signals - mfd.ru
Why analysts upgrade Milestone Pharmaceuticals Inc. stock2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
MIST Should I Buy - Intellectia AI
Milestone Appoints David Sandoval as General Counsel - Intellectia AI
MIST SEC FilingsMilestone Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Will Milestone Pharmaceuticals Inc. stock split attract more investorsMarket Growth Report & Real-Time Buy Signal Notifications - mfd.ru
What is the long term forecast for Milestone Pharmaceuticals Inc. stock2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru
What are the risks of holding Milestone Pharmaceuticals Inc.July 2025 Summary & Risk Adjusted Buy and Sell Alerts - mfd.ru
Milestone Pharmaceuticals appoints David Sandoval as general counsel By Investing.com - Investing.com Australia
Milestone Pharmaceuticals appoints David Sandoval as general counsel - Investing.com Nigeria
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer - The Manila Times
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Milestone Pharmaceuticals (MIST) CFO updates 204,000-share option to $1.96 - Stock Titan
Milestone Pharmaceuticals (MIST) Awards New Equity Options - GuruFocus
Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule - TipRanks
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Published on: 2026-02-03 14:31:32 - baoquankhu1.vn
Market Review: Is Milestone Pharmaceuticals Inc a momentum stockJuly 2025 Recap & Daily Oversold Bounce Ideas - baoquankhu1.vn
Milestone Pharmaceuticals (NASDAQ:MIST) Insider David Bharucha Sells 12,245 Shares - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Insider Lorenz Muller Sells 11,180 Shares - MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells $124,273.12 in Stock - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells $66,629.39 in Stock - MarketBeat
Jeffrey Edward Nelson Sells 58,007 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock - MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells 58,007 Shares of Stock - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) CEO Joseph Oliveto Sells 133,054 Shares - MarketBeat
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy - Yahoo Finance
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - Finviz
Finanzdaten der Milestone Pharmaceuticals Inc-Aktie (MIST)
Umsatz
Nettogewinn
Free Cashflow
ENV
Milestone Pharmaceuticals Inc-Aktie (MIST) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bharucha David | Chief Medical Officer |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
113,181 |
| Nelson Jeffrey Edward | Chief Operating Officer |
Dec 15 '25 |
Sale |
2.32 |
58,007 |
134,576 |
41,993 |
| Nelson Jeffrey Edward | Chief Operating Officer |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
49,848 |
| Muller Lorenz | Chief Commercial Officer |
Dec 15 '25 |
Sale |
2.32 |
53,566 |
124,273 |
196,486 |
| Muller Lorenz | Chief Commercial Officer |
Jan 26 '26 |
Sale |
1.93 |
11,180 |
21,577 |
205,406 |
| Hasija Amit | CFO & EVP of Corp. Development |
Dec 15 '25 |
Sale |
2.32 |
58,007 |
134,576 |
91,993 |
| Hasija Amit | CFO & EVP of Corp. Development |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
99,848 |
| Oliveto Joseph | President and CEO |
Dec 15 '25 |
Sale |
2.32 |
133,054 |
308,685 |
450,667 |
| Oliveto Joseph | President and CEO |
Jan 26 '26 |
Sale |
1.93 |
34,523 |
66,629 |
482,744 |
| Oliveto Joseph | President and CEO |
Jan 08 '26 |
Sale |
2.25 |
43,000 |
96,750 |
303,721 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):